DermResearch and NFlection Therapeutics Seeking Participants for Cutaneous Neurofibroma Clinical Trial
Author: DermResearch Inc.
Published On: 10/05/2020
Cutaneous neurofibromas are a common occurrence in our NF1 population. DermResearch and NFlection Therapeutics are searching for individuals with cutaneous neurofibromas to participate in a clinical trial. Qualified participants ages 18 and up will be seen by a board-certified dermatologist and compensated up to $1025 for time and travel. Insurance is not required, and there will be no cost to you.
This study will enroll and treat subjects with cutaneous neurofibromas with NFX-179, a topical study drug. Eligible subjects will receive treatment for 28 days and be observed by a study doctor for approximately 56 days. Subjects will be randomly assigned to 1 of 4 treatment groups. 3 of the treatment groups will receive a specific dose NFX-179, and 1 group will receive placebo. The subject, study doctor, and NFlection Therapeutics will not know what treatment group each subject is assigned.
To learn more about the study and trial locations, please visit the Clinical Trials site. For questions or further information on how to participate, please visit the DermResearch site or call 512-349-0500.